AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"US Oncology Network","sponsor":"Elevation Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elevation Oncology and US Oncology Research Ink Collaboration in Support of Phase 2 CRESTONE Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"US Oncology Network","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by US Oncology Network

    Menu

    US Oncology Network

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              US Oncology Network

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Onc...

              Details:

              Survivorship of women with advanced ovarian cancer has improved, primarily the result of 2 key agents, bevacizumab and Poly (ADP-ribose) polymerase inhibitors. In ATHENA trial, demonstrate the efficacy and safety of a third agent Rubraca (rucaparib) for primary treatment.

              Lead Product(s): Rucaparib Camsylate,Nivolumab

              Therapeutic Area: Oncology Product Name: Rubraca

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              US Oncology Network

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Elevation Oncology and US Oncology Research Ink Collaboration in Support of Phase 2 CRESTONE Study

              Details:

              Under this collaboration Elevation Oncology will utilize US Oncology Research Selected Trials for Accelerated Rollout program for patient enrollment in the registration-enabling Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion.

              Lead Product(s): Seribantumab

              Therapeutic Area: Oncology Product Name: MM-121

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Elevation Oncology

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration September 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biopharma Group offers CDMO services with expertise in contract R&D for dried products & liquid formulations.
              Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
              Post Enquiry
              POST ENQUIRY